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ABSTRACT 
Objective: The present study aimed to evaluate the cardioprotective effects of ethyl acetate and methanolartichoke extracts(Cynara scolymus L.) 
against 5-Flurouracil (5-FU) induced cardiotoxicity in rats. 
Methods: Thirty-six albino rats were divided randomly and equallyin to six groups (each group with 6 rats): I, negative control, received (2 
ml/kg/d)of dimethyl sulfoxide (DMSO) orally for 30 successive d; II, positive control, received (2 ml/kg/d) of (DMSO) orally for 30 successive d, and 
subsequently administered a single dose of 5-FU (150 mg/kg) by intraperitoneal injection on 27thd in assossiation with DSMO; III and IV, received 
(200 mg/kg/d) of oral methanol and ethyl acetate artichoke extracts respectivelyfor 30 successive d; V and VI, received(200 mg/kg/d) of oral 
methanol and ethyl acetate artichoke extracts respectively for 30 successive d,with a subsequently received single dose of 5-FU (150 mg/kg) by 
intraperitoneal injection on 27th d of the experiment.  
Results: Prophylactic treatment of ethyl acetate and methanol artichoke extracts significantly attenuates the increased level of serum cardiac 
troponin T (CTn-T) and tumor necrosis factor-α(TNF-α)caused by 5-FU-induced cardiotoxicity in experimental albino rats while it increases the 
serum level of total antioxidant capacity (T-AOC). 
Conclusion: Results of the present study suggest that methanol and ethyl acetate artichoke extracts may be an effective modulator in mitigating 5-
FU induced cardiotoxicity. 
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INTRODUCTION 
Antimetabolite, 5-fluorouracil (5-FU) has been effectively used for 
the treatment cancers of head, neck, breast and alimentary system 
[1], it is still a widely used anticancer drug since 1957 [2]. 5-FU is a 
heterocyclic aromatic organic compound with a structure similar to 
that of a pyrimidine molecules of DNA and RNA with an analogue of 
uracil with a fluorine atom at the C-5 position in place of hydrogen 
[3]. Due to its structure, 5-FU interferes with nucleoside metabolism 
and can be incorporated into RNA and DNA, leading to cytotoxicity 
and cell death [4, 5]. The alternative activation pathway of 5-
fluorouracil requires initial activation of the drug by the enzyme 
thymidine phosphorylase, which catalyses conversion of 5-FU to 
fluorodeoxyuridine (FUDR), the later is then phosphorylated by 
thymidine kinase (TK) to 5-fluoro-2'-deoxy uridine 5'-
monophosphate (5-FdUMP),an inhibitor of thymidylate synthase 
(TS)which is involved in the synthesis of thymidylate, thus 
preventing DNA synthesis; that leads to imbalanced cell growth and 
ultimately cell death [6]. In addition to bone marrow depression, 
gastrointestinal tract reaction, or even leucopenia and 
thrombocytopenia [7], 5-FU has several side effects such as cardio 
toxicity, nephro toxicity and hepatotoxicity which restrict its wide 
and extensive clinical use. Most of th 5-FU related organ toxicity is 
coupled with increased oxidative stress and apoptosis [8]. 
Artichoke (Cynara scolymus L.) is one of the world’s oldest medicinal 
plants with 2000 y history. It belongs to the family (Asteraceae) [9]. 
Originally it comes from the Mediterranean region and North Africa 
and then cultivated around the world. Artichoke was used as a food 
(as a digestive aid) and medicine by the ancient Egyptians, Greeks, 
and Romans [9]. It grows to a height of about 2 m and produces a 
large, violet-green flower head. The flower petals and fleshy flower 
bottoms are eaten as a vegetable throughout the world, which has 
led to its commercial cultivation in many parts of South and North 
America (chiefly California) as well as in Europe [9]. This plant is 
widely distributed in Iraq and normally located and found in the 
outer lines of the fields, water lines and humid watery soil. The plant 
flourishes in winter and it is usually harvested in February and 
March. Because of the artichokes durability, it is hardy to 
temperature below freezing [10]. Cynara scolymus L. is not only a 
good food, known for its pleasant bitter taste, but also an interesting 
and widespread herbal drug [11]. Artichoke leaves contain up to 2% 
phenolic acids, mainly 3-caffeoylquinic acid (chlorogenic acid), plus 
1.3-di-O-caffeoylquinic acid (cynarin), and caffeic acid; 0.4% bitter 
sesquiterpene lactones of which 47-83% is cynaropicrin; 0.11.0% 
flavonoids including the glycosides luteolin-7-β-rutinoside 
(scolymoside), luteolin-7-β-Dglucoside and luteolin-4-β-D-glucoside; 
phytosterols (taraxasterol); sugars; inulin; enzymes; and a volatile 
oil consisting mainly of the sesquiterpenes β-selinene and 
caryophyllene [12]. Artichoke leaf extract has been used as 
hepatoprotective [13], antimicrobial [14] and cholesterol reducing 
purposes [15]. Also it has been found to decrease the production of 
reactive oxygen species, the oxidation of low-density lipoproteins 
[16], lipid peroxidation [13], protein oxidation and increase the 
activity of glutathione peroxidase [17]. 
Several clinical studies have suggested that serum level of tumor 
necrosis factor-α (TNFα), interleukin-6 (IL-6), and C-reactive protein 
(CRP) are elevated in patients with congestive heart failure (CHF), 
regardless of the etiology of the condition [18]. 
The hepatoprotective,anti-inflammatory and anti-oxidant properties 
of artichoke extracts motivated us for designing this novel study to 
investigate the protective effects of different fractions of artichoke 
extracts (ethyl acetate and methanol)against 5-FU induced 
cardiotoxicity in albino rats. 
MATERIALS AND METHODS 
Reagents: Standard assays rat’s kits for Cardiac Troponin T(cTn-T) 
and TNF-α were abtained from CUSABIO BIOTECH CO., LTD., China. 
And for Total Antioxidant Capacity (TAOC) obtained from RANDOX 
Laboratories Ltd., Ardmore, Diamond Road, Crumlin, Co. Antrim, 
United Kingdom, BT29 4QY. 
Chemicals and drugs: 5-Fluorouracil (5-FU) obtained from EBEWE 
Pharma Ges.b.H.KG, Austria and (DMSO) from Sigma ,USA. 
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Plant material: The plant was collected from the garden of medicinal 
plants at the Department of Pharmacognosy and medicinal 
plants/college of pharmacy/University of Baghdad. The leaves of the 
plant were dried in the shade at room temperature, then rendered 
into a fine powder by using electrical mill. 
Extraction of the plant: 750 g of powdered leaves were extracted by 
soxhlet, using 3000 ml from each of petroleum ether, ethyl acetate 
and methanol successively as solvents, each extract was filtered and 
evaporated to dryness under reduced pressure using rotary 
evaporator,after that the collected amount was weighted.  
Preparation of extracts for injection: A known weights from the 
dried ethyl acetate and methanol artichoke extracts was dissolved in 
(DSMO) to get a concentration of 40 mg/ml. 
Animals and treatment 
Thirty-six female albino rats of 1-2 mo old (average body weight 150-
220 g) were obtained from animal house of the College of 
Pharmacy/University of Baghdad. The animals were acclimatized 
under standard laboratory conditions for 2w prior to treatment. They 
had free access to standard diet and water. They were maintained 
under standard condition of temperature(30°C), humidity and 
light/dark cycles. All the experimental studies were conducted by 
inconformity with the guidance for care and standard experimental 
animals of our college ethical protocol. The animals used in this study 
were divided equally into six groups each group with 6 rats as follow: 
Group I, negative control, received (2 ml/kg/d) of (DMSO) orally for 
30 successive d; Group II, positive control,received (2 ml/kg/d)of 
(DMSO) orally for 30 successive d, and subsequently administered a 
single dose of 5-FU (150 mg/kg) by intraperitoneal injection on 27thd 
in association with DMSO; Group III, received(200 mg/kg/d)of 
methanol artichoke extract orally for 30 successive d; Group IV, 
received (200 mg/kg/d)of ethyl acetate artichoke extract orally for 30 
successive d; Group V, received (200 mg/kg/d) of methanol artichoke 
extract orally for 30 successive d with a subsequently single 
intraperitoneal dose of 5-FU (150 mg/kg) on 27th d in association with 
methanol extract; Group VI,received(200 mg/kg/d)of ethyl acetate 
artichoke extracts orally 30 successive d with a subsequently single 
intra peritoneal dose of 5-FU (150 mg/kg) on 27th d in association with 
ethyl acetate extract. After 24 h of the end of the experimental period 
(30 d), all the animals were sacrificed under light diethyl ether 
anesthesia and blood samples were collected in clean test tubes by 
intracardiac puncturing of rats and allowed to clot at room 
temperature. 
Biochemical assessment 
The serum was separated by centrifugation for 20 min at 3600 
round per minute(r. p. m.) and stored into eppendorff tubes at–20 °C 
to be used for determination and assessment of biochemical 
parameters: Rat Cardiac Troponin T (cTn-T), Tumor Necrosis 
Factor-alpha (TNF-α) and Total Antioxidant (TAO). 
Statistical analysis 
Data was subjected to statistical analysis and expressed as mean 
values±standard deviation (SD) of samples. The statistical 
significance of the differences between various groups was 
determined by student unpaired t-test. The differences were 
considered statically significant for ∗P<0.05. 
RESULTS 
5-FU in (Group ΙΙ) significantly (∗P<0.05) increases serum level of 
cardiac troponin T (table 1) and TNF-α (table 2) with respect to Group 
Ι,and significantly (∗P<0.05) decreases serum level of TAO (table 3) 
with respect to Group Ι. Administration of methanol and ethyl acetate 
artichoke extracts in association with 5-FU(Group Ѵ& VI respectively) 
significantly (∗P<0.05) decreases the serum level of cardiac troponin T 
(table 1) andTNF-α(table 2), while it significantly (∗P<0.05) increases 
the TAO serum level with respect to Group ΙΙ(table 3). 
Group ΙѴ shows no significant difference (∗P<0.05) in serum levels of 
cardiac troponin T, TNF-α, and TAO with respect to Group Ι, also group 
III shows no significant difference (∗P<0.05) in serum level of cardiac 
troponin T with respect to Group Ι, but it revealsa significant 
difference (∗P<0.05) in the serum level of TNF-α and TAO with respect 
to Group Ι. Groups Ѵ and ѴΙ revealed a significant difference (∗P<0.05) 
in serum level of cardiac troponin T, TNF-α, and TAO with respect to 
group Ι, they(Group Ѵ and ѴΙ ) also revealed significant difference 
(∗P<0.05) in serum level of cardiac troponin T, TNF-α, and TAO with 
respect to Group ΙΙΙ and Ι Ѵ respectively as shown in table 1, 2 and 3. 
Group V shows no significant difference (∗P<0.05) in serum level of 
cardiac troponin T and TAO with respect to group ѴI, while it shows 
a significant difference (∗P<0.05) in serum level of TNF-αwith 
respect to group ѴI, as shown in table.1, 2 and 3. 
 
Table 1: The effects of ethyl acetate and methanol artichoke extracts (200 mg/kg) on serum level of cardiac troponin T in albino rats with 
5-FU induced cardiotoxicity, data are expressed as mean±SD,n =6,∗p<0.05. SD is standard deviation,5-FU is5-Fluorouracil and DSMO is 
dimethyl sulfoxide 
Groups Type of treatment Serum cardiac troponin 
T ng/l (mean±SD) 
I DMSO (2 ml/kg/d) orally for 30successive d 24.8±8.262 
II DMSO (2 ml/kg/d)  orally for 30 successive d+5-FU (150 mg/kg) single intraperitoneal dose on 27th d  60.8±8.72 ∗ 
III Methanol extract (200 mg/kg/d) for 30 successive d 32.83±8.6 sa 
IV Ethyl acetate extract  (200 mg/kg/d) for 30 successive d 31.11±6.66 sA 
V Methanol extract  (200 mg/kg/d) for 30 successive d+5-FU(150 mg/kg) single intraperitoneal dose on 27th d 43.8±5.65 bs∗ 
VI Ethyl acetate extract  (200 mg/kg/d) for 30 successive d+5-FU(150 mg/kg) single intraperitoneal dose on 27th d 47.8±7.13 Bs∗ 
-(*): Significantly different with respect to group Ι (∗p<0.05), -Values of groups III & V with non-identical subscripts (a, b) are significantly different 
(∗p<0.05), -Values of groups IV & VI with non-identical subscripts (A, B) are significantly different (∗p<0.05), -s subscript: significant difference with 
respect to the 5-FU treated group, -n: Number of animals. 
 
Table 2: The effects of ethyl acetate and methanol artichoke extracts (200 mg/kg) on serum level of TNF-α (tumor necrosis factor - alpha) 
in albino rats with 5-FU induced cardiotoxicity,data are expressed as mean±SD, n =6,∗ p<0.05. SD is standard deviation, 5-FU is 5-
Fluorouracil and DSMO is dimethyl sulfoxide 
Groups Type of treatment Serum TNF-α ng/l 
(mean±SD) 
I DMSO (2 ml/kg/d)orally for 30 successive d 23.33±5.6 
II DMSO (2 ml/kg/d) orally for 30 successive d+5-FU (150 mg/kg) single intraperitoneal doseon 27th d  107.5±45 ∗ 
III Methanol extract (200 mg/kg/d) for 30 successive d 13.93±4.24 as∗ 
IV Ethyl acetate extract (200 mg/kg/d)for 30 successive d 32±25.86 As 
V Methanol extract (200 mg/kg/d)for 30 successive d+5-FU(150 mg/kg) single intraperitoneal dose on 27th d 49.3±22 bcs∗ 
VI Ethyl acetate extract (200 mg/kg/d)for 30 successive d+5-FU(150 mg/kg) single intraperitoneal dose on 27th d 68.5±14.8 BCs∗ 
-(*): Significantly different with respect to group Ι (∗p<0.05), -Values of groups III & V with non-identical subscripts (a, b) are significantly different 
(∗p<0.05), -Values of groups IV & VI with non-identical subscripts (A, B) are significantly different (∗p<0.05), -Values of groups V & VI with non-identical 
subscripts (C,c) are significantly different (∗p<0.05), -s subscript: significant difference with respect to the 5-FU treated group, -n: Number of animals 
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Table 3: The effects of ethyl acetate and methanol artichoke extracts (200 mg/kg) on serum level of TAO(total antioxidant) in albino rats 
with 5-FU induced cardiotoxicity, data are expressed as mean±SD, n =6,∗ p<0.05. SD is standard deviation, 5-FU is 5-Fluorouracil and 
DSMO is dimethyl sulfoxide 
Groups Type of treatment Serum TAO ng/l 
(mean±SD) 
I DMSO (2 ml/kg/d) orally for 30 successive d 1.40±0.044 
II DMSO (2 ml/kg/d) orally for 30 successive d+5-FU (150 mg/kg) single intraperitoneal dose on 27th d 1.30±0.075 ∗ 
III Methanol extract (200 mg/kg/d) for 30 successive d 1.70±0.112 sa∗ 
IV Ethyl acetate extract (200 mg/kg/d) for 30 successive d 1.42±0.021 As 
V Methanol extract (200 mg/kg/d)for 30 successive d+5-FU(150 mg/kg) single intraperitoneal dose on 27th d 1.59±0.034 sb∗ 
VI Ethyl acetate extract (200 mg/kg/d)for 30 successive d+5-FU(150 mg/kg) single intraperitoneal dose on 27th d 1.48±0.057 B∗ 
-(*): Significantly different with respect to group Ι (∗p<0.05), -Values of groups III & V with non-identical subscripts (a, b) are significantly different 
(∗p<0.05), -Values of groups IV & VI with non-identical subscripts (A, B) are significantly different (∗p<0.05), -s subscript: significant difference with 
respect to the 5-FU treated group, -n: Number of animals 
 
DISSCUSION 
Cardiotoxicity is one of the dangerous side effect of 5-FU, which 
often presents as myocardial ischemia, but to a lesser extent cardiac 
arrhythmia, hyper and hypotension, left ventricular dysfunction, 
cardiac arrest and sudden death [19-24]. The incidence of 5-FU 
induced cardiotoxicity varies between 0-35% and this may depend 
on dose, cardiac comorbidity and schedule of chemotherapy 
[19,20,22]. The clinical handling of 5-FU-induced cardiotoxicity is 
difficult as the pathophysiological mechanisms underlying this 
cardiotoxicity remain undefined [19,25]. However, several 
mechanisms have been proposed, including vascular endothelial 
damage followed by coagulation, ischemia secondary to coronary 
artery spasm, direct toxicity on the myocardium and thrombo 
genicity due to altered rheological factors [25].  
The pathogenesis of 5-FU induced cardiotoxicity may involve 
oxidative stress with increased levels of superoxide anion after 5-FU 
treatment [26]. The activities of Super Oxide Dismutase (SOD) and 
Glutathion Peroxidase(GSH-Px)were lowered in 5-FU treated guinea 
pigs [27] demonstrating a reduced antioxidant capacity. If not 
eliminated by cellular antioxidant systems, superoxide anions can 
generate the highly reactive and toxic hydroxyl radicals through the 
Haber–Weiss reaction, which is catalyzed by iron [28,29]. Increased 
reactive oxygen species (ROS) levels inside cells lead to oxidation of 
macromolecules, including lipids, nucleic acids, and proteins, 
thereby disturbing cellular functions [29]. The present study 
confirms the cardiotoxicity of 5-FU, as evidenced by the significantly 
(∗P<0.05) elevation in serum level of cardiac troponin T and TNF-α 
with increased oxidative stress manifested as significantly (∗P<0.05) 
decrease in TAO serum level. 
Detection of elevated concentrations of cardiac biomarkers in blood 
is a sign of cardiac injury which could be due to supply–demand 
imbalance, toxic effects, or haemo dynamic stress [30]. Creatinine 
kinase (CK), serum AST, lactate dehydrogenase, myoglobin, and 
troponins are some of these markers [31]. 
In the last decade, many studies focused on the possibility that 
inflammation may complicate the clinical course of heart failure 
(HF) via impairing cardiac contractility, promoting apoptosis and 
fibrosis and ultimately leading to myocardial remodeling [32, 33]. 
Furthermore, the chemotherapy initiates the release of (ROS) and 
pro-inflammatory cytokines, such as tumor necrosis factor-α (TNF-
α) and interleukins (IL)-1 and 6, which play an indirect role in the 
amplification of intestinal damage [34]. 
Tumor Necrosis Factor-alpha (TNF-α) is a major mediator of 
inflammation [35]. ROS generation, after TNF-α binding, has been 
reported to be involved in both cell survival and cell death, and the 
main source of ROS generation that contributes to TNF-α-induced 
cell death is the mitochondrion [35, 36]. ROS modulator 1 (Romo1) 
is localized in the mitochondria and induces mitochondrial ROS 
production through complex III of the mitochondrial electron 
transport chain [37-39]. Romo1 expression is induced by an external 
stimulus such as 5-FU, and it is up regulated in senescent cells and in 
most cancer cells [37,38,40]. Romo1 is a molecular bridge between 
TNF-α signaling and the mitochondria for ROS production that triggers 
TNF-α-mediated apoptosis [35]. Another study reported that NADPH 
oxidase is the source of ROS generation after TNF-α treatment [41]. 
ROS are known to contribute to cell death by inducing mitochondrial 
membrane permeabilization and sustaining c-Jun N-terminal kinase 
(JNK) activation [42, 43]. There are several reports regarding the 
mechanism of JNK-induced apoptosis in response to TNF-α [35]. 
The present study has shown a successful reduction in cardiotoxicity 
and inflammation induced by 5-FU in albino rats after treatment 
with ethyl acetate and methanol artichoke extracts, this was 
reflected by attenuation in serum level of cardiac troponin T and 
TNF-α with significant decrease in the oxidative stress manifested 
by elevation of the serum levels of total antioxidant capacity (T-AOC) 
of treated rats. This antioxidant and anti-inflammatory effects of 
artichoke extracts are attributed to phenolic compounds [44,45]. 
Different studies about artichoke extracts have demonstrated their 
health-protective potential, especially their hepatoprotective [46,47] 
and health promoting properties in preventing cardiovascular 
disease (CVD) by its hypo lipidemic action [48] or by upregulation of 
endothelial nitric-oxide synthase (eNOS)gene expression and eNOS 
protein expression [49]. Also, artichoke extracts have anticancer 
effects by increasing apoptosis either in hepatocellular carcinoma in 
rats [50] or human hepatoma cells [51]. In fact, artichoke is 
potentially good source of antioxidant activity because it contains 
large amounts of caffeic acids [52, 53]. Caffeic acid derivatives are 
the main phenolic compounds in artichoke heads, with a wide range 
of caffeoylquinic acid derivatives as (cynarin) [54] with chlorogenic 
acid (5-Ocaffeoylquinicacid) as the most important of these 
derivatives [55]. Other phenolics such as the flavonoids apigenin and 
luteolin (both glucosides and rutinosides) [56] as well as different 
cyanidin caffeoylglucoside derivatives [57] have been identified. 
The effects of artichoke extracts and its constituents have also been 
investigated for activity against oxidative stress in studies using 
human leucocytes [58]. The extracts demonstrated a concentration-
dependent inhibition of oxidative stress induced by several agents, 
such as hydrogen peroxide, that generates reactive oxygen species. 
The constituents; cynarin, caffeic acid, chlorogenic acid and luteolin 
also showed concentration-dependent oxidative stress inhibitory 
activity [58]. In addition,artichoke extracts has marked protective 
properties against oxidative stress induced by inflammatory 
mediators and oxidize-LDL in cultured endothelial cells and 
monocytes [16]. In vivo, the administration of an edible artichoke in 
rats has shown that artichoke extract increased the level of 
glutathione peroxidase activity in erythrocyte and decreased the 
level of 2-Aminoadipic semialdehyde (a protein oxidation 
biomarker) [59]. 
Flavonoids protective effects against many diseases, in particular 
cardiovascular diseases and cancer, are attributed to two properties: 
(1) antioxidant activity and (2) inhibition of certain enzymes such as 
xanthine oxidase (enzyme catalyzes the conversion of both 
hypoxanthine to xanthine and xanthine to uric acid while reducing 
O2 to O2-• and H2O2 [60]) [61, 62]. Many studies have suggested 
that flavonoids exhibit biological activities, including anti allergenic, 
antiviral, anti-inflammatory, vasodilationactions. These pharma-
cological effects are linked to the antioxidant properties of 
Najim et al. 
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flavonoids. Flavonoids can express these properties by: (1) 
suppressing ROS formation through inhibiting some enzymes or 
chelating trace elements involved in free radical production, (2) 
scavenging radical species and more specially the ROS, and/or (3) 
up-regulating or protecting antioxidant defense [61]. 
CONCLUSION 
Our results suggest that ethyl acetate and methanol artichoke 
extracts have protective effects against 5-FU-induced cardiotoxicity 
in albino rats. However, before a conclusive statement can be made 
on the potential antioxidant activity of artichoke extracts as an 
adjunct to 5-FU therapy, there is a need for further long-term 
chronic studies for different fractions of artichoke extracts. 
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